PPA
PVLA

Parametric Portfolio Associates’s Palvella Therapeutics PVLA Stock Holding History

Parametric Portfolio Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-327
Closed -$67K – 3598
2021
Q1 		$67K Sell
327
-241
-42% -$52.7K ﹤0.01% 4006
2020
Q4 		$114K Buy
568
+239
+73% +$49.7K ﹤0.01% 3872
2020
Q3 		$55K Sell
329
-14
-4% -$3.19K ﹤0.01% 3856
2020
Q2 		$85K Sell
343
-87
-20% -$20.3K ﹤0.01% 3811
2020
Q1 		$78K Buy
430
+147
+52% +$37K ﹤0.01% 3766
2019
Q4 		$82K Sell
283
-42
-13% -$11.6K ﹤0.01% 3883
2019
Q3 		$89K Buy
325
+60
+23% +$23.2K ﹤0.01% 3847
2019
Q2 		$100K Buy
265
+54
+26% +$16.1K ﹤0.01% 3842
2019
Q1 		$57K Buy
+211
New +$50.1K ﹤0.01% 3878
2018
Q4 		– Sell
-196
Closed -$88K – 3972
2018
Q3 		$88K Sell
196
-78
-28% -$33.9K ﹤0.01% 3862
2018
Q2 		$111K Sell
274
-1,465
-84% -$697K ﹤0.01% 3793
2018
Q1 		$949K Buy
+1,739
New +$1.08M ﹤0.01% 3048

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Parametric Portfolio Associates's PVLA Position: Q2 2021 in Review

Parametric Portfolio Associates sold out of Palvella Therapeutics (PVLA) in Q2 2021, closing a stake of 327 shares — an estimated $67K sold.

Parametric Portfolio Associates first reported a position in PVLA in Q1 2018 and held it in 12 quarters. The position peaked at $949K in Q1 2018. 73 funds tracked by Wall St. Rank hold PVLA as of Q2 2021.

  • Parametric Portfolio Associates reported no remaining Palvella Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 327 Palvella Therapeutics shares in Q2 2021, an estimated $67K.
  • Parametric Portfolio Associates first reported a position in Palvella Therapeutics in Q1 2018 and held it in 12 quarters.
  • Parametric Portfolio Associates's Palvella Therapeutics position peaked at $949K in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2021.

Based on Parametric Portfolio Associates's 13F filing for Q2 2021, filed 13 Aug 2021.